Futura Medical Share Chat (FUM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Futura Medical Plc	LSE:FUM	London	Ordinary Share	GB0033278473	ORD 0.2P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+2.50p	+9.80%	28.00p	27.50p	28.50p	28.50p	26.50p	26.75p	1,973,759	16:04:22

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-7.2	-4.5	-	57.30

Futura Medical Share Discussion Threads

Showing 16876 to 16897 of 16900 messages

Chat Pages: 676 675 674 673 672 671 670 669 668 667 666 665 Older

Date	Subject	Author	Discuss
19/6/2019 16:13	mike whatever you paid I think you'll get your money back.Too many false dawns in this stock, and too little institutional presence but it looks like finally it's coming together.I think Liberum are now supporting it.At least we know what we're aiming for and we'll know by end of Dec we'll have conclusive results.Seems LO still selling - 175K sale lunchtime.	wantage	Read Full Thread Reply
19/6/2019 14:18	if only CSD500 had had regular progress RNSs, like Med is now having, I wouldn't be sitting on a thumping loss on FUM like I am	mikethebike4	Read Full Thread Reply
19/6/2019 12:18	I do rather like this sort of confidence from the Broker The broker added that the Phase 3 trial for MED2002 was “low-risk̶1; as the study currently had 20 realistic outcomes, only one of which would mean the treatment could not be launched commercially. As a result, Liberum said Futura’s current share price was a “very attractive entry-point” with even its risk-adjusted valuation pointing to upside in the shares of over 100%.	ragnarr	Read Full Thread Reply
19/6/2019 11:20	https://www.proactiveinvestors.co.uk/companies/news/219194/futura-medical-looking-ahead-to-completion-of-key-phase-iii-ed-trial-219194.html ???	horneblower	Read Full Thread Reply
19/6/2019 11:20	J777J I think you could be right. The main focus is obviously on MED2005 but there is definitely news due at some point re TPR100 TPR100 - topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism In July 2018, Thornton & Ross, a subsidiary of STADA AG, Futura's UK commercialisation partner for TPR100, filed a marketing authorisation application for the product with the UK Medicines and Healthcare products Regulatory Agency (MHRA). In February 2019, the MHRA responded with some questions requiring some additional laboratory studies which are in the process of being conducted in order to address the MHRA's questions and allow the submission to progress and complete the review process. Futura has ongoing commercial discussions with several potential distribution partners for territories outside of the UK. Finalisation of such regional licensing deals is expected to be after UK regulatory approval.	ragnarr	Read Full Thread Reply
19/6/2019 10:48	Ken James sounds extremely chipper. Still in ongoing commercial negotiations. My hunch remains a deal maybe closer than many think.	j777j	Read Full Thread Reply
19/6/2019 10:33	Proactive Investor Interview: Sorry - I am struggling to upload the link here.	alchemist1010	Read Full Thread Reply
19/6/2019 09:24	Pleased to see recruitment completed on time and on budget, well done FUM.	rrr	Read Full Thread Reply
19/6/2019 09:18	Should hopefully see a nice steady rise to maybe 35/40 over the coming months and assuming data is good at the end of the year the sky is the limit then	ragnarr	Read Full Thread Reply
19/6/2019 07:49	Ties in nicely with this "Futura Medical PLC’s (LON:FUM) data from a Phase 3 trial of its MED2005 erectile dysfunction treatment could drive the share price up over 500% according to analysts at Liberum Capital, who on Monday initiated the stock with a ‘buy’ rating and 60p target price. In its initiation note, the ‘house’ broker for the AIM-listed pharma firm said they expected positive data from the Phase 3 trial for MED2002, which is expected to be delivered by December this year." So maybe November we will know the outcome.	j777j	Read Full Thread Reply
19/6/2019 07:14	James Barder, Chief Executive Officer, Futura Medical said: "We are extremely pleased to complete recruitment of over 1,000 patients for the first European Phase 3 study, "FM57", of MED2005, within our expected timelines and budget and I would like to thank all parties involved in reaching this important milestone. The Company's focus is now on the Phase 3 data read-out at the end of the year, which we hope will significantly clinically de-risk MED2005, and help provide commercial partners with greater certainty around the potential opportunity it presents." The potential market for this product is large with potential peak sales in excess of US $1 billion. If MED2005 is approved, there is an estimated $560M prescription-only market potential (sources: Decision Resources and Cello), and an estimated incremental $660M+ market potential as an over-the-counter (OTC) product, in markets where switch is possible. (source: Ipsos Mori forecasts commissioned by Futura).	j777j	Read Full Thread Reply
18/6/2019 17:01	Good old Grannypants always knows best.	j777j	Read Full Thread Reply
17/6/2019 14:33	As my dear old gran used to tell me "all good things come to those that wait"	ragnarr	Read Full Thread Reply
17/6/2019 13:27	Simply need US bio fund or two onboard and the shares will rerate.	j777j	Read Full Thread Reply
17/6/2019 12:19	Liberum's figures are ultra conservative and that simply amplifies the value here.	j777j	Read Full Thread Reply
17/6/2019 11:56	Thanks J777J.	rrr	Read Full Thread Reply
17/6/2019 11:47	Liberum "The multi-billion dollar market for erectile dysfunction (ED) therapies continues to be dominated by PDE-5 inhibitors, despite a slow onset of action and negative side-effects. We believe Futura’s MED2005 addresses these issues and expect positive P3 data in December. Our confidence is driven by compelling P2 data, a non-binary set of potential outcomes, and a rock-solid safety profile. With a market cap of just £50m vs a peak sales potential of c.£500m, we think the market misses this low risk potential. BUY." "Key catalyst due by Dec 2019 Unlike with most drug discovery businesses, there is not long to wait for the key catalyst, with the headline P3 data due by December. This could drive >500% upside." Yes >500% upside!! "Liberum view: Headline data from FM57 is due by the end of December 2019, which is the key catalyst for the shares. This data alone should be enough to secure a significant outlicensing agreement, but more importantly de-risk the confirmatory second P3 study." "We have not provided much detail on potential competition in the pipeline, as frankly we do not see any at this stage."	j777j	Read Full Thread Reply
17/6/2019 11:34	Just a game of patience here, happy holding.. chart looks good though! One on the move, outdoors be under valued too (C4XD) dyor as usual	ny boy	Read Full Thread Reply
17/6/2019 09:49	>>>martinelwick You can download the note from Research tree https://www.research-tree.com/companies/uk/pharmaceuticals/futura-medical	timbo003	Read Full Thread Reply
17/6/2019 08:46	Hi can you provide the link.	martinelwick	Read Full Thread Reply
17/6/2019 08:18	Liberum 60p price target fair value and 137p high end	j777j	Read Full Thread Reply
17/6/2019 08:10	Bullish research report from Liberum today."High probability of success,low valuation......"	j777j	Read Full Thread Reply

Chat Pages: 676 675 674 673 672 671 670 669 668 667 666 665 Older

Your Recent History

LSE

FUM

Futura Med..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.